Innoviva (INVA) Specialty Therapeutics, a subsidiary of Innoviva, announced that the U.S. FDA has approved Nuzolvence for oral suspension, a first-in-class, single-dose oral medication for the treatment of uncomplicated urogenital gonorrhea in adults and pediatric patients 12 years and older weighing at least 35 kg. The development of Nuzolvence was part of a private, not-for-profit collaboration with The Global Antibiotic Research and Development Partnership, which sponsored and led the Phase 3 clinical trial that supported FDA approval.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INVA:
- Innoviva’s Zoliflodacin: A Promising Antibiotic Driving Buy Rating Amidst Urgent Need for Drug-Resistant Infection Solutions
- Innoviva announces Lancet publication of ‘positive’ Zoliflodacin Phase 3 data
- Roth Capital healthcare analyst holds an analyst/industry conference call
- Innoviva Reports Strong Q3 2025 Financial Results
- Innoviva management to meet virtually with Oppenheimer